Are treatment-induced changes in KCCQ scores correlated with clinical outcomes in patients with chronic heart failure?
Treatment-induced changes in KCCQ scores correlate significantly with clinical outcomes in phase 3 heart failure trials, supporting its potential as a surrogate endpoint.
Treatment-induced changes in KCCQ scores are significantly correlated with clinical outcomes in phase 3 HF trials. These findings support KCCQ as a promising candidate intermediate endpoint that provides supportive evidence for the clinical benefit of HF therapies. However, our results remain hypothesis-generating, and further validation using individual patient data and cross-mechanism studies is warranted before KCCQ can be formally established as a regulatory surrogate endpoint.
Fukuta et al. (Tue,) studied this question.